利奥西呱对不可手术或复发慢性血栓栓塞性肺动脉高压的血流动力学效应
在慢性血栓栓塞性肺动脉高压可溶性鸟苷酸环化酶刺激剂试验1中,261例不可手术或持续性/复发性慢性血栓栓塞性肺动脉高压患者随机接受利奥西呱(至2.5 mg每日三次)或安慰剂治疗。利奥西呱降低了不可手术和持续性/复发性患者的肺血管阻力,并降低了平均肺动脉压;不可手术患者的心脏指数改善,而持续性/复发性患者的心脏指数变化未达统计学显著。结论认为利奥西呱改善了不可手术或持续性/复发性慢性血栓栓塞性肺动脉高压患者的血流动力学。
要点
- 利奥西呱降低不可手术慢性血栓栓塞性肺动脉高压患者肺血管阻力(最小二乘均值差-285 dyn·s/cm⁵)。
- 利奥西呱降低持续性/复发性慢性血栓栓塞性肺动脉高压患者肺血管阻力(最小二乘均值差-131 dyn·s/cm⁵)。
- 不可手术患者心脏指数改善,持续性/复发性患者心脏指数变化未达统计学显著。
核心结论
- 利奥西呱改善了不可手术或持续性/复发性慢性血栓栓塞性肺动脉高压患者的血流动力学。
研究设计与样本
- 慢性血栓栓塞性肺动脉高压可溶性鸟苷酸环化酶刺激剂试验1为随机对照研究,纳入261例不可手术或持续性/复发性慢性血栓栓塞性肺动脉高压患者(平均年龄59±14岁,66%为女性),随机接受利奥西呱(至2.5 mg每日三次)或安慰剂,在基线和第16周评估血流动力学参数。
主要发现
- 利奥西呱降低不可手术患者(n=189)肺血管阻力,最小二乘均值差为-285 dyn·s/cm⁵(95%CI -357至-213;p<0.0001)。
- 利奥西呱降低持续性/复发性患者(n=72)肺血管阻力,最小二乘均值差为-131 dyn·s/cm⁵(95%CI -214至-48;p=0.0025)。
- 不可手术患者心脏指数改善,最小二乘均值差为+0.6 L/min/m²(95%CI 0.4至0.7;p<0.0001);持续性/复发性患者心脏指数变化为+0.2 L/min/m²(95%CI -0.1至0.5;p=0.17),未达统计学显著。
- 不可手术患者平均肺动脉压降低-4.7 mm Hg(95%CI -6.9至-2.6;p<0.0001),持续性/复发性患者降低-4.8 mm Hg(95%CI -8.2至-1.5;p=0.0055)。
- 全部患者中,6分钟步行距离变化与肺血管阻力变化相关(r=-0.29(95%CI -0.41至-0.17);p<0.0001),与心脏指数变化相关(r=0.23(95%CI 0.10至0.35);p=0.0004)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: We compared the haemodynamic effects of riociguat in patients with inoperable chronic thromboembolic pulmonary hypertension (CTEPH) or persistent/recurrent CTEPH after pulmonary endarterectomy in the Chronic Thromboembolic Pulmonary Hypertension Soluble Guanylate Cyclase-Stimulator Trial 1 study. METHODS: Patients with inoperable or persistent/recurrent CTEPH (n=261; mean± SD age 59±14 years; 66% women) were randomised to riociguat (up to 2.5 mg three times daily) or placebo. Haemodynamic parameters were assessed at baseline and week 16. RESULTS: Riociguat decreased pulmonary vascular resistance (PVR) in inoperable (n=189; least-squares mean difference: -285 dyn s/cm5 (95% CI -357 to -213); p<0.0001) and persistent/recurrent (n=72; -131 dyn s/cm5 (95% CI -214 to -48); p=0.0025) patients. Cardiac index improved in inoperable patients by a least-squares mean difference of +0.6 L/min/m2 (95% CI 0.4 to 0.7; p<0.0001), while in persistent/recurrent patients the change was +0.2 L/min/m2 (95% CI -0.1 to 0.5; p=0.17). Mean pulmonary artery pressure decreased in inoperable and persistent/recurrent patients(-4.7 mm Hg (95% CI -6.9 to -2.6; p<0.0001 and -4.8 mm Hg (-8.2 to -1.5; p=0.0055), respectively). For all patients, changes in 6 min walk distance correlated with changes in PVR (r=-0.29 (95% CI -0.41 to -0.17); p<0.0001) and cardiac index (r=0.23 (95% CI 0.10 to 0.35); p=0.0004). CONCLUSIONS: Riociguat improved haemodynamics in patients with inoperable CTEPH or persistent/recurrent CTEPH. TRIAL REGISTRATION NUMBER: NCT00855465.
引用
- Kim NH, D'Armini AM, Grimminger F, et al. Haemodynamic effects of riociguat in inoperable/recurrent chronic thromboembolic pulmonary hypertension. Heart. 2016. PMID: 28011757. doi:10.1136/heartjnl-2016-309621
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。